Catalyst Dossier · compiled by Celia 🧫

Bristol-Myers Squibb Company (BMY)

Pharmaceutical Preparations · market cap $110.3B · as of 2026-06-23

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-30

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Bristol-Myers Squibb (BMY) is a large-cap pharmaceutical company with ~$110B market cap and $48B in annual revenues, anchored by Eliquis (30% of 2025 revenue) and Opdivo (21%), both facing meaningful patent/biosimilar headwinds. The company carries a substantial $36.9B net debt load while sustaining ~$10B annual R&D spend, with a pipeline spanning oncology, immunology, cardiovascular, and neurology across numerous Phase 2 and Phase 3 assets.

The catalyst path

2026-07-30Earningsimp 5/10
2026-11-24 (est.)Phase 3 · KarXTimp 9/10
2026-12-31 (est.)Phase 3imp 7/10
2027-02-05 (est.)Phase 2 · Nivolumabimp 7/10
2027-03-11 (est.)Phase 3 · Ipilimumabimp 9/10
2027-05-28 (est.)PDUFA · Camzyosimp 8/10

Pipeline

Asset	Phase	Indication
Arlocabtagene Autoleucel	Phase 2	Multiple Myeloma
Rituximab	Phase 2	Lymphoma
CC-97540	Phase 2	Lupus Erythematosus, Systemic
Vinflunine	Phase 3	Bladder Cancer
Capecitabine	Phase 3	Breast Neoplasms
Cyclophosphamide	Phase 3	Relapsed or Refractory Multiple Myeloma (RRMM)
BMS-650032	Phase 2	Chronic Hepatitis C
Nivolumab	Phase 3	Brain Neoplasms
Ozanimod	Phase 3	Colitis, Ulcerative
Paclitaxel	Phase 3	Lung Cancer
Irbesartan	Phase 3	Congestive Heart Failure
Deucravacitinib	Phase 3	Plaque Psoriasis
stavudine extended-release, lamivudine, efavirenz	Phase 3	HIV Infections
paclitaxel (PTX)	Phase 3	Breast Cancer
BMS-986177	Phase 2	Acute Ischemic Stroke
BMS-790052 (Daclatasvir)	Phase 3	Hepatitis C
Entecavir (ETV)	Phase 3	Hepatitis B
Relatlimab	Phase 3	Lymphoma, Non-Hodgkin
Dasatinib	Phase 3	Chronic Phase Chronic Myeloid Leukemia
BMS-790052	Phase 2	Hepatitis C Infection

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by Celia. The catalyst path & pipeline above are free.

See Pro

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by Celia. Not financial advice.